Answers are grounded in this paper and cite their sources.
Pancreatic cancer, a highly malignant tumor, poses a severe threat to human health, and widely applicable therapeutic targets with substantial clinical benefits remain limited. SPAG4 exhibits limited expression in normal tissues but is aberrantly activated and significantly upregulated in multiple tumors; its role in pancreatic cancer remains unclear. Multi-database bioinformatics analysis was employed to explore SPAG4’s potential function in pancreatic cancer. In vitro assays (CCK-8, colony formation, EdU, Transwell, and scratch wound healing) were performed to evaluate the effects of SPAG4 on pancreatic cancer cell phenotypes. SPAG4 upregulation in multiple tumors correlated with poor prognosis. Integrated bulk transcriptomic and single-cell RNA-seq analyses showed SPAG4 overexpression in pancreatic cancer, which was associated with poor survival and adverse clinicopathological features. Functional enrichment analysis based on SPAG4-associated transcriptomic alterations suggested potential involvement in oncogenic processes, including cellular metabolism, genomic maintenance, cell-cycle progression, intercellular adhesion, growth regulation, and MAPK/ERK signaling. SPAG4 expression was also associated with TIMER-estimated immune infiltration. In vitro assays showed that SPAG4 modulation altered pancreatic cancer cell proliferation, migration, and invasion.
No takes yet. Share an insight, caveat, or question.
Ni et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: